Global Ibuprofen Market By Type (Rx, OTC), By Form (Tablets, Capsules, Suspension), By Indication (Inflammatory Disease, Rheumatoid Arthritis, Pain/Fever/Dysmenorrhea), By Distribution Channel (Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2031
- Published date: Apr 2022
- Report ID: 16110
- Number of Pages: 351
- Format:
- keyboard_arrow_up
Ibuprofen is mostly used in the treatment of chronic diseases such as cancer, cardiovascular diseases, arthritis, etc., and this element is expected to foster increased revenue growth prospects for this global market over the forecast period.
Market.US announces the publication of its most recently generated research report titled, “Global Ibuprofen Market by Type (Rx (Medical Prescription), OTC (Over-The-Counter)), Form (Tablets, Capsules, Suspension), Indication(Inflammatory Disease, Rheumatoid Arthritis, Pain/Fever/Dysmenorrhea, Other Indications), Distribution Channel(Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies), and by Region – Global Forecast to 2031”, which offers a holistic view of the Global Ibuprofen Market through systematic segmentation that covers every aspect of the target market.
The Global Ibuprofen Market is projected to be US$ 7,379.6 Mn in 2021 to reach US$ 10,402.2 Mn by 2031 at a CAGR of 3.6%.
Ibuprofen is a Nonsteroidal Anti-Inflammatory Drug (NSAID), and it belongs to a group category of propionic acid derivatives. The drug was first introduced in 1961, and was initially marketed as “Brufen”. Currently, it is sold under several trade names such as Advil, Motrin, and Nuprin. It has also been licensed for Over-The-Counter (OTC) distribution and usage.
It is commonly used to treat fever, pain, and inflammation. Ibuprofen is available in the form of capsules, tablets, or powder. It is often prescribed for rheumatic musculoskeletal disorders and is also taken without the need for a prescription to treat minor aches and pains. Ibuprofen is a first-choice drug in its class as it has a low incidence rate of adverse effects. It is rapidly metabolized, usually leaving the body within 24 hours via urination.
It is used for its analgesic and anti-inflammatory effects in the treatment of diseases such as rheumatoid arthritis (including juvenile rheumatoid arthritis or Still’s a disease), ankylosing spondylitis, osteoarthritis, and other non-rheumatoid (seronegative) arthropathies.
Ibuprofen is not only used in the treatment of articular rheumatic conditions, but also for specific conditions such as frozen shoulder (capsulitis), tendonitis, bursitis, tenosynovitis, lower back pain, as well as for soft-tissue injuries like strains and sprains. Apart from these, it has analgesic effects in the relief of mild to moderate pains, such as dysmenorrhea, dental, and post-operative pain.
Global Ibuprofen Market Revenue (US$ Mn), 2021–2031
According to the World Health Organization (WHO), 60 percent of fatalities are caused by major chronic diseases, and the Global Burden of Disease Study puts that number at 43 percent (GBD). These estimates are expected to rise as the prevalence of these diseases rises as a result of changing lifestyles. Because ibuprofen is commonly used to treat chronic conditions including cancer, cardiovascular disease, arthritis, and others, this factor is likely to boost revenue growth possibilities for this global market throughout the forecast period.
Ibuprofen can cause nausea, dyspepsia, constipation, headaches, diarrhea, rashes, dizziness, and salt and fluid retention, according to clinical investigations undertaken by many governmental and non-governmental agencies. Kidney impairment worsened asthma, elevated potassium levels in the blood, heart failure, and other severe effects have also been documented. Such consequences are projected to stifle the global market’s revenue growth.
Ibuprofen has been certified by the Food and Drug Administration (FDA) as a safe therapeutic option for children and infants under the age of six months. It’s also used in the short-term treatment of illnesses in youngsters, such as fever, toothaches, gastrointestinal pain, and so on. It’s also been utilized to shut the Patent Ductus Arteriosus (PDA), a persistent opening between the two major blood arteries originating from the heart that develops frequently in premature babies. Ibuprofen is projected to profit from a variety of lucrative revenue development opportunities in the near future as a result of its favorable benefits.
In recent years, the availability of OTC medications such as Ibuprofen on e-commerce portals has rapidly increased. The emergence of e-commerce pharmacy portals like dokteronline.com, drugs.com, cvs.com, vidal.ru, consultaremedios.com.br, mCHEMIST.com, Medidart.com, and others, as well as the availability of prescription and non-prescription drugs on these websites, are all trends that are likely to continue to provide a significant revenue boost to this global industry.
Global Ibuprofen Market Attractiveness Analysis by Type, 2015–2031
The global Ibuprofen market is segmented on the basis of type, form, indication, distribution channel, and regions. Based on type market segmentation, the OTC sub-segment is expected to account for a majority revenue share of this target market. On the basis of form, the tablet sub-segment is expected to generate a majority revenue share over the forecast period. With respect to the indication market segmentation, the pain/fever/dysmenorrhea sub-segment accounted for the majority of the market share.
With regards to distribution channels, retailer pharmacies accounted for the maximum number of revenue shares, followed by online pharmacies. On the basis of region, the markets in the North America region are projected to account for the majority share in terms of revenue of the global Ibuprofen market, and these markets are projected to maintain their respective market positions over the forecast period.
The research report on the global ibuprofen market includes profiles of some of the major companies such as– Novartis AG, Pfizer Inc., Abbott Laboratories, Gilead Sciences, Inc., Merck KGaA, Astellas Pharma Inc., Glenmark Pharmaceuticals Ltd., NATCO Pharma Ltd., Basilea Pharmaceutical AG, and Leadiant Biosciences Inc. among others.
Global Ibuprofen Market Segmentation Based on Type, Form, Indication, Distribution Channel, and Region
Based on Type
- Rx (Medical Prescription)
- OTC (Over-The-Counter)
Based on Form
- Tablets
- Capsules
- Suspension
Based on Indication
- Inflammatory Disease
- Rheumatoid Arthritis
- Pain/Fever/Dysmenorrhea
- Other Indications
Based on Distribution Channel
- Hospital Pharmacies
- Retailer Pharmacies
- Online Pharmacies
Based on Key Players:
- Novartis AG
- Pfizer Inc.
- Abbott Laboratories
- Gilead Sciences Inc.
- Merck KGaA
- Astellas Pharma Inc.
- Glenmark Pharmaceuticals Ltd.
- NATCO Pharma Ltd.
- Basilea Pharmaceutical AG
- Leadiant Biosciences Inc.
- others
Based on Region
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
For the Ibuprofen Market research study, the following years have been considered to estimate the market size:
Attribute Report Details Historical Years
2016-2020
Base Year
2021
Estimated Year
2022
Short Term Projection Year
2028
Projected Year
2023
Long Term Projection Year
2032
Report Coverage
Competitive Landscape, Revenue analysis, Company Share Analysis, Manufacturers Analysis, Volume by Manufacturers, Key Segments, Key company analysis, Market Trends, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis, strategy for existing players to grab maximum market share, and more.
Regional Scope
North America, Europe, Asia-Pacific, South America, Middle East & Africa
Country Scope
United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa
- Novartis AG Company Profile
- Pfizer Inc Company Profile
- Abbott Laboratories
- Gilead Sciences Inc.
- Merck KGaA Company Profile
- Astellas Pharma Inc.
- Glenmark Pharmaceuticals Ltd.
- NATCO Pharma Ltd.
- Basilea Pharmaceutical AG
- Leadiant Biosciences Inc.
- others
- settingsSettings
Our Clients
Single User
$5,999
$2,999
USD / per unit
save 50% |
Multi User
$7,999
$3,499
USD / per unit
save 55% |
Corporate User
$12,999
$4,499
USD / per unit
save 65% | |
---|---|---|---|
e-Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 2,999) | Buy Now ($ 3,499) | Buy Now ($ 4,499) |